Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor [Phase 2]
Phase 2 trial evaluating two doses of ATIR101 (T-lymphocyte enriched, host alloreactive T-cell depleted) in hematologic malignancy patients …
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor [Phase 2]
Phase 2 trial update on ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with hematologic malignancies p…
-
CLINICAL_TRIALS trial_result · 2020-12-08Clinical Trial Update: Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) [Phase 1, Phase 2]
Extension study evaluating nilotinib in adults with imatinib-resistant/intolerant CML or relapse/refractory Philadelphia-positive ALL; compl…
-
CLINICAL_TRIALS trial_result · 2020-12-03Clinical Trial Update: Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial update of Modified Hyper-CVAD regimen for acute lymphoblastic leukemia has completed with posted results.
-
CLINICAL_TRIALS research · 2020-11-23Clinical Trial Update: GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia [Phase 1, Phase 2]
Clinical trial exploring bendamustine as GVHD prophylaxis after transplantation in refractory leukemia, reported in Phase 1/Phase 2.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-11-20Clinical Trial Update: Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias [Phase 3]
Phase 3 trial evaluating a personalized preparative regimen prior to T-depleted allogeneic HSCT in children with chemoresistant acute leukem…
-
CLINICAL_TRIALS trial_result · 2020-10-27Clinical Trial Update: A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL [Phase 1, Phase 2]
Phase 1/2 pilot trial of decitabine and vorinostat with chemotherapy for relapsed acute lymphoblastic leukemia (ALL) in children; study term…
-
FDA approval · 2020-10-23FDA Approved: CLOFARABINE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved a generic clofarabine product (Clofarabine) from Meitheal Pharmaceuticals Inc. under an original application. It is indicated f…
-
CLINICAL_TRIALS trial_result · 2020-10-12Clinical Trial Update: Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial evaluating donor lymphocyte infusion with azacitidine to prevent relapse after stem cell transplantation.
-
CLINICAL_TRIALS trial_result · 2020-10-08Clinical Trial Update: De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients [Phase 2]
Phase 2 clinical trial update for de novo adult Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) patients.
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM [Phase 1, Phase 2]
Phase 1/2 clinical trial update for NiCord (umbilical cord blood-derived ex vivo expanded cells) in hematological malignancies, including AL…
-
CLINICAL_TRIALS trial_result · 2020-09-14Clinical Trial Update: Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) [Phase 3]
Phase 3 trial update on blinatumomab in Chinese adults with relapsed/refractory B-precursor acute lymphoblastic leukemia; results completed …
-
CLINICAL_TRIALS trial_result · 2020-09-10Clinical Trial Update: Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases [Phase 2]
Phase 2 trial evaluating myeloablative umbilical cord blood transplantation in various hematological diseases has completed with results pos…
-
CLINICAL_TRIALS trial_result · 2020-09-09Clinical Trial Update: ABT-751 With Chemotherapy for Relapsed Pediatric ALL [Phase 1, Phase 2]
Phase 1/Phase 2 trial of ABT-751 combined with chemotherapy for relapsed/recurrent pediatric acute lymphoblastic leukemia was terminated wit…
-
CLINICAL_TRIALS trial_result · 2020-08-31Clinical Trial Update: Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma [Phase 1]
Phase 1 trial of anti-CD19 white blood cells in children and young adults with B-cell leukemia or lymphoma completed; results posted in 2020…
-
CLINICAL_TRIALS trial_result · 2020-08-12Clinical Trial Update: Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A clinical trial evaluating alemtuzumab and clofarabine for relapsed or refractory acute lymphoblastic leukemia was terminated; results were…
-
CLINICAL_TRIALS trial_result · 2020-08-12Clinical Trial Update: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT [Phase 1, Phase 2]
Clinical trial update on an IL-15 super agonist ALT-803 for relapse of hematologic malignancies after allogeneic stem cell transplant, compl…
-
CLINICAL_TRIALS trial_result · 2020-08-11Clinical Trial Update: Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 trial of pembrolizumab for acute lymphoblastic leukemia with minimal residual disease was terminated; results posted.
-
FDA approval · 2020-08-10FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GLEEVEC (imatinib mesylate) from Novartis, approving changes to the product labeling based o…
-
CLINICAL_TRIALS trial_result · 2020-07-24Clinical Trial Update: Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies [Phase 2]
A Phase 2 clinical trial investigating adoptive regulatory T cells to suppress acute graft-versus-host disease after umbilical cord blood st…
-
FDA approval · 2020-07-23FDA Approved: IMATINIB MESYLATE — Original Application (BluePoint Laboratories)
FDA approved imatinib mesylate as an original-application generic drug for BluePoint Laboratories.
-
CLINICAL_TRIALS trial_result · 2020-07-13Clinical Trial Update: Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) [Phase 3]
Phase 3 pediatric trial comparing blinatumomab to standard chemotherapy in high-risk first-relapse B-precursor acute lymphoblastic leukemia …
-
FDA approval · 2020-07-10FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) from Takeda Pharmaceuticals America, Inc., approving changes t…
-
CLINICAL_TRIALS withdrawal · 2020-07-09Clinical Trial Update: Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia [Phase 3]
Phase 3 trial comparing tisagenlecleucel against blinatumomab or inotuzumab for relapsed/refractory B-cell precursor ALL has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-07-08Clinical Trial Update: Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients [Phase 2, Phase 3]
A phase 2/3 trial evaluated whether vitamin B6 and vitamin B12 can protect against vincristine-induced neurotoxicity in patients with acute …